WARF: P06105US

  • Assigned to WARF as biological material.

Mouse Monoclonal Antibodies to the Human Nuclear Receptor, Estrogen-Related Receptor Alpha


Richard Burgess, Nancy Thompson, Jennifer Lamberski, Janet Mertz, Elizabeth Vu, Adebanke Lesi, Richard Kraus

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing high quality, well characterized monoclonal antibodies to ERRalpha.
OVERVIEWEstrogen-related receptor alpha (ERRalpha) is a recently discovered biomarker and treatment target for breast cancer (See WARF reference number P03031US). However, few, if any reliable monoclonal antibodies to ERRalpha are commercially available.
THE INVENTIONUW-Madison researchers have developed high quality, well characterized monoclonal antibodies to ERRalpha. Because some of these antibodies bind antigen tightly but release it when eluted with a mixture of salt and a polyol, they are ideal for use in immunoaffinity chromatography.
  • Immunoprecipitations, including chromatin immunoprecipitation on arrays
  • Western blots
  • Immunoaffinity chromatography
  • Potentially useful as a cancer diagnostic tool or therapeutic drug
  • Some antibodies are useful for "supershifting" ERRalpha-DNA complexes during electrophoresis.
  • Those that are "polyol-responsive" are suitable for polyol-based purification of ERRalpha and associated proteins. 
For More Information About the Inventors
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.